Apollon Formularies plc Total Voting Rights (5970U)

TIDMAPOL

RNS Number : 5970U

Apollon Formularies plc

02 August 2022

2 August 2022

Apollon Formularies Plc

("Apollon" or the "Company")

Total Voting Rights

In accordance with the Financial Conduct Authority's Disclosure and Transparency Rules, the Company hereby announces that it has 771,191,266 ordinary shares of no par value each in issue, each share carrying the right to one vote.

This figure of 771,191,266 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

The directors of the Company accept responsibility for the contents of this announcement.

-ENDS-

For further information please contact:

Apollon Formularies

   Tel:    +44 771 198 0221 
   Stene Jacobs    stene@apollon.org.uk

Peterhouse Capital Limited (Corporate Adviser)

   Tel:    +44 207 220 9795 
   Guy Miller       gm@peterhousecapital.com

BlytheRay (Financial PR/IR-London)

   Tel:    +44 207 138 3204 
   Tim Blythe/Megan Ray    apollon@blytheray.com

About Apollon and Apollon Jamaica

Apollon Formularies plc is an international medical cannabis and medicinal mushroom pharmaceutical company headquartered in the United Kingdom. Apollon Formularies Jamaica Limited is a pharmaceutical company incorporated and operating in the Commonwealth of Jamaica since 2016. Apollon Jamaica is licensed by the Jamaican government's Cannabis Licensing Authority (CLA) to cultivate (R&D), perform research and development, process, and sell medical cannabis therapeutic products that include legal medical cannabis to treat various illnesses under medical supervision.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXPTMPTMTMMMLT

(END) Dow Jones Newswires

August 02, 2022 04:11 ET (08:11 GMT)

Apollon Formularies (AQSE:APOL)
Historical Stock Chart
From Mar 2024 to Apr 2024